First Trust NYSE Arca Biotechnology Index Fund

Most Recent

  • uploads///flasks _
    Company & Industry Overviews

    Why Exelixis Stock Soared 46% in November

    Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

    By Daniel Collins
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Vertex
    Company & Industry Overviews

    How Vertex Pharmaceuticals Is Positioned Financially

    In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Revenue Stream in Q2 2018

    Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year).

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///medic _
    Healthcare

    Ionis Pharmaceuticals Stock as of March 27, 2018

    Ionis Pharmaceuticals stock has fallen 6.9% over the last week. However, it rose 2.6% to close at $48.99 on March 26, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Nektar Therapeutics Sees Setbacks in Plans for Ciproflaxin DPI

    On November 16, 2017, the FDA’s Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics’ ciprofloxacin DPI.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Is Preparing for Commercial Launch of Patisiran

    To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Geographic Market Expansion to Boost Spinraza Sales in 2017

    In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza reported sales worth $73 million from international markets.

    By Margaret Patrick
  • uploads///Chart  OP
    Company & Industry Overviews

    How Gilead’s Other Products Performed in 2Q17

    Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Nuplazid Expected to Become a Leading Central Nervous System Drug

    On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.

    By Margaret Patrick
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Reports Revenue Growth in 2Q17

    Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.

    By Mike Benson
  • uploads///Chart  AMGN
    Miscellaneous

    The Rise of Amgen Stock in 2Q17

    Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Neurocrine Analysts reco
    Company & Industry Overviews

    Neurocrine Biosciences: Ingrezza, Collaborations, Ratings

    In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation Compared to Its Peers

    According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    United Therapeutics: Will RemoSynch Become a Key Growth Driver?

    United Therapeutics (UTHR) has developed a targeted strategy for a successful launch of its investigational drug device combination, the RemoSynch implantable pump system.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///acq flexibility
    Company & Industry Overviews

    How Could Gilead Sciences Restore Its Growth?

    With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.

    By Jillian Dabney
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///soliris
    Earnings Report

    What Are the Drivers behind the Success of Soliris?

    Following analysts’ projections, Soliris revenues in 3Q16 and 4Q16 should rise 9.0% and 10.0%, respectively, YoY to reach $725.9 million and $760.6 million, respectively.

    By Jillian Dabney
  • uploads///orkambis success
    Earnings Report

    Why Europe Is an Important Market for Vertex’s Orkambi

    Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

    By Jillian Dabney
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///revenue projections
    Company & Industry Overviews

    BioMarin to Cross $1 Billion Revenue in 2016

    BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.

    By Jillian Dabney
  • uploads///Orkambi
    Company & Industry Overviews

    Higher Discontinuations Are among Orkambi’s Concerns

    Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares to Its Peers

    Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

    By Mike Benson
  • uploads///revenue projections
    Company & Industry Overviews

    What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?

    During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.

    By Jillian Dabney
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///Orkambi
    Earnings Report

    How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16?

    With the continued uptake of Orkambi along with the label expansion efforts, Vertex Pharmaceuticals’s (VRTX) top line in fiscal 2016 is expected to reach $1.7 billion–$1.8 billion.

    By Jillian Dabney
  • uploads///soliris
    Earnings Report

    How Can Alexion Stay ahead of the Competition with Soliris?

    Soliris is Alexion Pharmaceuticals’ anchor of success. The drug was approved for paroxysmal nocturnal hemoglobinuria, or PNH, as a first indication in 2007.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016

    If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.

    By Margaret Patrick
  • uploads///valuation catalysts in H
    Company & Industry Overviews

    Inside BioMarin’s Big Plans for 3Q16

    BioMarin decided to withdraw its MAA (Marketing Authorization Application), given the expectation of a negative decision on the drug from the EMA.

    By Jillian Dabney
  • uploads///pipeline
    Company & Industry Overviews

    Understanding Alexion’s Robust Pipeline

    Alexion is expanding the label for its key drug Soliris. Along with Soliris, Alexion’s has several other key molecules in the advanced development stage.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics’ Adcirca Could Witness Strong Revenue Growth

    After acquiring commercial rights from Eli Lily (LLY) in 2008, United Therapeutics (UTHR) started marketing Adcirca in the US in 2009.

    By Margaret Patrick
  • uploads///acquisition
    Company & Industry Overviews

    Medivation Is for Sale: How Much Should It Get?

    Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

    By Jillian Dabney
  • uploads///praluent
    Earnings Report

    How Can Regeneron Pharmaceuticals Boost Revenue from Praluent?

    During the first quarter of 2016, Praluent sales came to $13 million.

    By Jillian Dabney
  • uploads///Share price
    Earnings Report

    Understanding Alexion’s Share Price Performance since Its Previous Earnings

    Alexion reported a revenue decline of 1.5% and an earnings decline of 2.2% in 1Q16, which surprised investors and led to a 6% fall in its share price.

    By Jillian Dabney
  • uploads///CF opportunity
    Earnings Report

    A Look at Vertex’s Cystic Fibrosis Patient Opportunity

    There are ~27,000 eligible patients for Vertex Pharmaceuticals’ Kalydeco and Orkambi. However, Vertex is only currently treating one-third of patients.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ Valuation: How Does It Compare?

    We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.

    By Mike Benson
  • uploads///breast Vs prostate cancer
    Company & Industry Overviews

    Could Xtandi’s Use for Breast Cancer Be a Valuation Driver?

    If Xtandi is successful in achieving a longer treatment duration of about ten months, it could earn up to $1 billion in the breast cancer space.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///Naglazyme
    Company & Industry Overviews

    BioMarin’s Naglazyme Sales Dipped by 31.3% Last Year

    In 2015, Naglazyme contribution toward BioMarin Pharmaceutical’s (BMRN) total revenue was ~$303 million, down 31.3% YoY.

    By Jillian Dabney
  • uploads///Orkambi
    Company & Industry Overviews

    What’s Vertex’s Label Expansion Strategy for Orkambi?

    In November 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received approval from the European Commission to treat patients 12 years and older with two copies of the F508del mutation.

    By Jillian Dabney
  • uploads///segmental revenue
    Earnings Report

    Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15

    Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.

    By Jillian Dabney
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///Financial Projections
    Earnings Report

    Will Regeneron’s Earnings Continue to Impress Investors?

    Regeneron’s net margin during 3Q15 was ~18.5%. Historically, the net margin has been very volatile. It fluctuated from 8% to 24% for the last ten quarters.

    By Jillian Dabney
  • uploads///Orkambi revenue projections
    Earnings Report

    Orkambi: Recent Addition to the Vertex Portfolio

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.

    By Jillian Dabney
  • uploads///Pomalyst and Abraxane Revenue Part
    Earnings Report

    Pomalyst and Abraxane Revenues Are Critical for Celgene

    Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

    By Peter Neil
  • uploads///cphd pm
    Earnings Report

    Cepheid’s Revenue and Income Fell in 3Q15

    After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15.

    By Gabriel Kane
  • uploads///Graph
    Miscellaneous

    Alkermes’s Multi-Pronged Strategy for Its Aristada Launch

    Alkermes plans a multi-pronged strategy for Aristada’s successful launch, which will involve flexible usage, effective pricing, and additional research.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.